Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Physics

Cancer Oncology

Medicine

Internal Medicine

Hematology

Show all topics

DOI

10.1016/s1470-2045(19)30152-4